Table 2.

Autonomic, cranial, and peripheral neuropathies reported in patients receiving the combination of vincristine and antifungal azoles.

Adverse Event	Signs and Symptoms	All Azoles N = 47 (%)	Itra N = 35 (%)	Keto N = 8 (%)	Posa N = 3 (%)	Vori N = 1 (%)
Autonomic neuropathy		18 (38.3)	17 (48.6)	1 (12.5)	0 (0)	0 (0)
	Hypertension		14 (40)
	Inability to pass urine		1 (2.9)
	Incontinence		1 (2.9)
	Neurogenic bladder		1 (2.9)	1 (12.5)
	Orthostatic hypotension		1 (2.9)
	Palpable bladder		1 (2.9)
	Sweating		1 (2.9)
	Decrease in anal tone		1 (2.9)
Cranial neuropathy		11 (23.4)	6 (17.1)	5 (62.5)	0 (0)	0 (0)
	Jaw pain		1 (2.9)	3 (37.5)
	Opthalmoplegia		1 (2.9)
	Ptosis		5 (14.3)
	Transient visual loss			1 (12.5)
	Weak gag reflex			1 (12.5)
Peripheral neuropathy		28 (59.6)	19 (54.3)	6 (75)	2 (66.7)	1 (100)
	Loss of deep tendon reflexes		8 (22.9)	1 (12.5)	2 (66.7)	1 (100)
	Severe foot drop/steppage gait		2 (5.7)		1 (33.3)	1 (100)
	Areflexia		2 (5.7)	5 (62.5)
	Arthralgia		2 (5.7)
	Back pain		1 (2.9)	1 (12.5)
	Difficult/inability to walk or stand up		3 (8.6)		1 (33.3)
	Diffuse muscle weakness		2 (5.7)		1 (33.3)
	Hypothenar and thenar wasting		1 (2.9)
	Muscle cramps		1 (2.9)
	Myalgia		4 (11.4)
	Neurotoxicity of extremities		4 (11.4)		1 (33.3)
	Neuropathic pain/paresthesia		5 (14.3)	1 (12.5)	1 (33.3)
	Paralysis of extremities		2 (5.7)
	Weakness of extremities		3 (8.6)	5 (62.5)

itra = itraconazole;keto=ketoconazole;posa = posaconazole;vori = voriconazole;N = total number of patients.